Arrowhead to Present at Upcoming Scientific Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate" (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.
Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society Davos, Switzerland, June 14, 2013
A workshop presentation titled, Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA, will be presented by Christine Wooddell, Ph.D., Senior Scientist;
4th RNAi Research & Therapeutics Conference San Francisco, CA, USA, June 21, 2013
A featured presentation titled, DPC Technology for siRNA Delivery: Moving from Platform to Pipeline, will be presented by David Lewis, Ph.D., Vice President, Biology;
The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine Basel, Switzerland, June 26, 2013
An oral presentation titled, A Novel Hepatitis B Treatment with RNAi, will be presented by Christopher Anzalone, Ph.D., President and CEO.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to email@example.com
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Source: Arrowhead Research CorporationCopyright Business Wire 2013